menu
    • menu

    Company profile for Antisense Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Antisense Therapeutics Limited (ANP.ASX) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Antisense TherapeuticsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    6 Wallace Avenue Toorak, Victoria, 3142
    Telephone
    Telephone
    +61 (3) 9827 8999
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.antisense.com.au/
    Linkedin
    Linkedin
    https://au.linkedin.com/company/antisense-therapeutics-ltd.
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    COVID-19 study- Novel blood markers as future diagnostic & therapeutic targets
    COVID-19 study- Novel blood markers as future diagnostic & therapeutic targets

    23 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/23/2503212/0/en/Long-COVID-19-study-identifies-novel-blood-markers-as-potential-diagnostic-and-therapeutic-targets.html

    GLOBENEWSWIRE
    23 Aug 2022
    Share Share
    Antisense Tx to present poster at world’s largest NMD conference
    Antisense Tx to present poster at world’s largest NMD conference

    09 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/09/2400311/0/en/Antisense-Therapeutics-to-present-poster-at-world-s-largest-NMD-conference.html

    GLOBENEWSWIRE
    09 Mar 2022
    Share Share
    Antisense Therapeutics Announces a Poster Presentation on the MDA
    Antisense Therapeutics Announces a Poster Presentation on the MDA

    11 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200611005274/en/Antisense-Therapeutics-Announces-Poster-Presentation-Muscular-Dystrophy

    BUSINESSWIRE
    11 Jun 2020
    Share Share
    Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint
    Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint

    21 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200521005411/en

    BUSINESSWIRE
    21 May 2020
    Share Share
    Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint
    Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint

    21 May 2020

    // MARKETWATCH

    https://www.marketwatch.com/press-release/antisense-atl1102-final-phase-ii-dmd-results-meet-primary-endpoint-and-exceed-expectations-on-secondary-endpoints-2020-05-21?mod=mw_more_headlines&tesla=y

    MARKETWATCH
    21 May 2020
    Share Share
    Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial
    Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial

    17 Dec 2019

    // BIO SPACE

    https://www.biospace.com/article/releases/positive-results-reaffirm-plans-to-advance-atl1102-for-dmd-to-phase-iib-trial/?s=62

    BIO SPACE
    17 Dec 2019
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search